$MED
MEDIFAST INC Stock $med

$med Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024005620 Filed on February 20, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$174.7M	$191.0M	$1.072B
YoY Change	-49.93%	-43.36%	-32.94%
Cost Of Revenue	$47.45M	$49.65M	$296.2M
YoY Change	-53.75%	-52.1%	-35.35%
Gross Profit	$127.3M	$141.4M	$775.9M
YoY Change	-48.34%	-39.48%	-31.97%
Gross Profit Margin	72.85%	74.01%	72.37%
Selling, General & Admin	$119.4M	$131.5M	$649.4M
YoY Change	-38.12%	-34.19%	-32.04%
% of Gross Profit	93.76%	93.01%	83.71%
Research & Development	$1.000M	$1.200M	$4.600M
YoY Change	0.0%	0.0%	2.22%
% of Gross Profit	0.79%	0.85%	0.59%
Depreciation & Amortization	$3.261M	$3.307M	$13.11M
YoY Change	9.65%	11.95%	19.37%
% of Gross Profit	2.56%	2.34%	1.69%
Operating Expenses	$119.4M	$132.7M	$654.0M
YoY Change	-38.12%	-33.98%	-31.88%
Operating Profit	$7.940M	$8.676M	$126.4M
YoY Change	-85.16%	-73.39%	-31.6%
Interest Expense	$1.223M	$1.176M	$2.490M
YoY Change	-775.69%	-746.15%	-455.21%
% of Operating Profit	15.4%	13.55%	1.97%
Other Income/Expense, Net	$3.645M	-$50.00K	$2.395M
YoY Change	-2102.75%	455.56%	-420.62%
Pretax Income	$11.59M	$9.802M	$128.8M
YoY Change	-78.28%	-69.75%	-30.02%
Income Tax	$3.269M	$3.767M	$29.38M
% Of Pretax Income	28.22%	38.43%	22.81%
Net Earnings	$8.316M	$6.035M	$99.42M
YoY Change	-79.19%	-77.24%	-30.75%
Net Earnings / Revenue	4.76%	3.16%	9.27%
Basic Earnings Per Share	$0.76		$9.13
Diluted Earnings Per Share	$0.76	$0.55	$9.10
COMMON SHARES
Basic Shares Outstanding	10.90M shares	10.89M shares	10.88M shares
Diluted Shares Outstanding	10.96M shares		10.92M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$156.4M	$150.0M	$150.0M
YoY Change	26.41%	71.1%	71.1%
Cash & Equivalents	$97.47M	$94.44M	$94.44M
Short-Term Investments	$58.96M	$55.60M	$55.60M
Other Short-Term Assets	$11.41M	$10.67M	$10.67M
YoY Change	17.97%	-34.29%	-34.29%
Inventory	$46.27M	$54.59M	$54.59M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$219.6M	$224.0M	$224.0M
YoY Change	-4.66%	0.56%	0.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$50.99M	$51.47M	$67.11M
YoY Change	-8.89%	-10.0%	-11.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$13.65M	$14.65M	$18.77M
YoY Change	-0.44%	17.61%	5.53%
Total Long-Term Assets	$83.18M	$85.88M	$85.88M
YoY Change	-8.89%	-8.08%	-8.08%
TOTAL ASSETS
Total Short-Term Assets	$219.6M	$224.0M	$224.0M
Total Long-Term Assets	$83.18M	$85.88M	$85.88M
Total Assets	$302.8M	$309.9M	$309.9M
YoY Change	-5.86%	-1.99%	-1.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$71.23M	$86.42M	$47.96M
YoY Change	-37.13%	-35.84%	-18.26%
Accrued Expenses	$5.958M	$5.885M	$42.36M
YoY Change	10.11%	1.89%	-22.7%
Deferred Revenue		$574.0K
YoY Change		-92.2%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$77.19M	$92.30M	$92.30M
YoY Change	-41.41%	-34.49%	-34.49%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$14.61M	$16.13M	$16.13M
YoY Change	-22.95%	-20.46%	-20.46%
Total Long-Term Liabilities	$14.61M	$16.13M	$16.13M
YoY Change	-22.95%	-20.46%	-20.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$77.19M	$92.30M	$92.30M
Total Long-Term Liabilities	$14.61M	$16.13M	$16.13M
Total Liabilities	$91.80M	$108.4M	$108.4M
YoY Change	-39.09%	-32.72%	-32.72%
SHAREHOLDERS EQUITY
Retained Earnings	$183.0M	$174.6M
YoY Change	20.51%	24.88%
Common Stock	$11.00K	$11.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$211.0M	$201.5M	$201.5M
YoY Change
Total Liabilities & Shareholders Equity	$302.8M	$309.9M	$309.9M
YoY Change	-5.86%	-1.99%	-1.99%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$8.316M	$6.035M	$99.42M
YoY Change	-79.19%	-77.24%	-30.75%
Depreciation, Depletion And Amortization	$3.261M	$3.307M	$13.11M
YoY Change	9.65%	11.95%	19.37%
Cash From Operating Activities	$7.282M	$10.56M	$147.7M
YoY Change	-88.63%	-79.6%	-24.11%
INVESTING ACTIVITIES
Capital Expenditures	$1.841M	$983.0K	$6.483M
YoY Change	-12.96%	-89.15%	-61.14%
Acquisitions
YoY Change
Other Investing Activities	-$934.0K	-$9.764M	-$54.56M
YoY Change			-1135.96%
Cash From Investing Activities	-$2.775M	-$10.75M	-$61.05M
YoY Change	31.21%	18.57%	434.84%
FINANCING ACTIVITIES
Cash Dividend Paid	$710.0K		$73.02M
YoY Change	-96.29%		1.95%
Common Stock Issuance & Retirement, Net			$3.602M
YoY Change			-97.15%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.491M	-17.89M	-$79.79M
YoY Change	-94.24%	-26.48%	-60.02%
NET CHANGE
Cash From Operating Activities	$7.282M	10.56M	$147.7M
Cash From Investing Activities	-$2.775M	-10.75M	-$61.05M
Cash From Financing Activities	-$1.491M	-17.89M	-$79.79M
Net Change In Cash	$3.031M	-18.08M	$6.749M
YoY Change	-91.59%	-198.56%	-140.92%
FREE CASH FLOW
Cash From Operating Activities	$7.282M	$10.56M	$147.7M
Capital Expenditures	$1.841M	$983.0K	$6.483M
Free Cash Flow	$5.441M	$9.574M	$141.2M
YoY Change	-91.22%	-77.57%	-20.64%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2000	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1373000	usd
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-945000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000910329
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-31573
CY2023	dei	Entity Registrant Name EntityRegistrantName	Medifast, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	13-3714405
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 International Drive
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	21202
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Baltimore
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023	dei	City Area Code CityAreaCode	410
CY2023	dei	Local Phone Number LocalPhoneNumber	581-8042
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	MED
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1000000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10895595	shares
CY2023	dei	Auditor Firm AuditorFirmId	49
CY2023	dei	Auditor Name AuditorName	RSM US LLP
CY2023	dei	Auditor Location AuditorLocation	Baltimore, Maryland
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1072054000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1598577000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1526087000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	296204000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	458163000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	398490000	usd
CY2023	us-gaap	Gross Profit GrossProfit	775850000	usd
CY2022	us-gaap	Gross Profit GrossProfit	1140414000	usd
CY2021	us-gaap	Gross Profit GrossProfit	1127597000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	649448000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	955608000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	911356000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	126402000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	184806000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	216241000	usd
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2490000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-701000	usd
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-231000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-46000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	119000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-112000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	99415000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	9.13
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	12.82
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	9.10
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	12.73
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	13.89
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10884000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11195000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11705000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10921000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11276000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11813000	shares
CY2023	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	4.95
CY2022	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	6.56
CY2021	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	5.68
CY2023	us-gaap	Net Income Loss NetIncomeLoss	99415000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	143568000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	164031000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-72000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-67000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	112000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	296000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-20000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-42000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	224000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-87000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	70000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	99639000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	143481000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	164101000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94440000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87691000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	54591000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	118856000	usd
CY2023Q4	med	Investment Securities Current InvestmentSecuritiesCurrent	55601000	usd
CY2022Q4	med	Investment Securities Current InvestmentSecuritiesCurrent	0	usd
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	8727000	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	0	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10670000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16237000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	224029000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	222784000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	51467000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57185000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15645000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18460000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14650000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12456000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	4117000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	5328000	usd
CY2023Q4	us-gaap	Assets Assets	309908000	usd
CY2022Q4	us-gaap	Assets Assets	316213000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	86415000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	134690000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	428000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5885000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5776000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	92300000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	140894000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16127000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20275000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	108427000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	161169000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10896000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10928000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10896000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10873000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	11000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	11000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26573000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	21555000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	248000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	24000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	174649000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	139852000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	54000	shares
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	0	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	6398000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	201481000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	155044000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	309908000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	316213000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	99415000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	143568000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	164031000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13107000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10980000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6812000	usd
CY2023	med	Operating Lease Expense Non Cash OperatingLeaseExpenseNonCash	4607000	usd
CY2022	med	Operating Lease Expense Non Cash OperatingLeaseExpenseNonCash	6098000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	8188000	usd
CY2023	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	169000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	811000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3715000	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	150000	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	126651000	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-9155000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5567000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-97000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9887000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4694000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3412000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4543000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-35707000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-37594000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	54380000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	147657000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	194570000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	94545000	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	54564000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	5267000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	5145000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6483000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16681000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34209000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-61047000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11414000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29064000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	188000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	811000	usd
CY2023	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	3358000	usd
CY2022	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	1516000	usd
CY2021	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	6089000	usd
CY2023	us-gaap	Payments Of Dividends PaymentsOfDividends	73017000	usd
CY2022	us-gaap	Payments Of Dividends PaymentsOfDividends	71620000	usd
CY2021	us-gaap	Payments Of Dividends PaymentsOfDividends	63856000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3602000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	126445000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55999000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-79789000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-199581000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-125133000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-72000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-67000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	112000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6749000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16492000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-59540000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87691000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104183000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	163723000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94440000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87691000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104183000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	34255000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	37212000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	56758000	usd
CY2023	us-gaap	Dividends Cash DividendsCash	1407000	usd
CY2022	us-gaap	Dividends Cash DividendsCash	19641000	usd
CY2021	us-gaap	Dividends Cash DividendsCash	17186000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	157246000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	164031000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	9596000	usd
CY2023Q4	us-gaap	Due From Banks DueFromBanks	3700000	usd
CY2022Q4	us-gaap	Due From Banks DueFromBanks	7400000	usd
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	6089000	usd
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	55999000	usd
CY2021	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	70000	usd
CY2021	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	67192000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	202474000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	143568000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	11053000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1516000	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	126445000	usd
CY2022	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	1000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-87000	usd
CY2022	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	74002000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	155044000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	99415000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	8188000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	188000	usd
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3358000	usd
CY2023	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	3602000	usd
CY2023	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	224000	usd
CY2023	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	54618000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	201481000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Certain amounts reported for prior periods have been reclassified to be consistent with the current period presentation. No reclassification in the consolidated financial statements had a material impact on the presentation.</span></div>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our cash and cash equivalents and available-for-sale debt securities are maintained at several financial institutions and the balances with these financial institutions often exceed the amount of insurance provided on such accounts by the Federal Deposit Insurance Corporation. The cash and cash equivalents generally are maintained with financial institutions with reputable credit, and therefore bear minimal credit risk. Historically, we have not experienced any losses due to such concentration of credit risk.</span></div>
CY2023	us-gaap	Advertising Expense AdvertisingExpense	3400000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4600000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4500000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4400000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	7944000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	12670000	usd
CY2023Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	1962000	usd
CY2022Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	3611000	usd
CY2023Q4	med	Inventory Non Food Finished Goods InventoryNonFoodFinishedGoods	3703000	usd
CY2022Q4	med	Inventory Non Food Finished Goods InventoryNonFoodFinishedGoods	8738000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	43248000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	97675000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2266000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3838000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	54591000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	118856000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	98773000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	97126000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	47306000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39941000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	51467000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57185000	usd
CY2023	us-gaap	Depreciation Depreciation	10000000.0	usd
CY2022	us-gaap	Depreciation Depreciation	7900000	usd
CY2021	us-gaap	Depreciation Depreciation	5700000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	39193000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	53120000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	17184000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	13581000	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	13277000	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	23633000	usd
CY2023Q4	med	Unrecognized Tax Liability Including Interest And Penalties Current UnrecognizedTaxLiabilityIncludingInterestAndPenaltiesCurrent	8763000	usd
CY2022Q4	med	Unrecognized Tax Liability Including Interest And Penalties Current UnrecognizedTaxLiabilityIncludingInterestAndPenaltiesCurrent	5547000	usd
CY2023Q4	med	Promotional Sales Incentive Accruals PromotionalSalesIncentiveAccruals	4923000	usd
CY2022Q4	med	Promotional Sales Incentive Accruals PromotionalSalesIncentiveAccruals	10240000	usd
CY2023Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	1407000	usd
CY2022Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	19641000	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1094000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1571000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	574000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7357000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	86415000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	134690000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	99415000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	143568000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	164031000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10884000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11195000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11705000	shares
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	37000	shares
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	81000	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	108000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10921000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11276000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11813000	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	9.13
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	12.82
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	14.01
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	9.10
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	12.73
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	13.89
CY2023Q4	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	21500000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10900000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	600000	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	1600000	shares
CY2019Q3	med	Stock Repurchase Program Additional Shares Authorized StockRepurchaseProgramAdditionalSharesAuthorized	2000000	shares
CY2023	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	31000	shares
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	739000	shares
CY2023Q4	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	1300000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	32000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	54.98
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	32000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	54.98
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	7000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	27.40
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	25000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	62.20
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	32000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	54.98
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	25000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	62.20
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	28000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	52.76
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P45M
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	100000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	100000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	200000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	800000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	400000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5900000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	149162000	usd
CY2023Q4	med	Investment Securities Unrealized Gains InvestmentSecuritiesUnrealizedGains	569000	usd
CY2023	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	31000	shares
CY2022	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	9000	shares
CY2021	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	22000	shares
CY2023	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	224000	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8188000	usd
CY2022	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	184000	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11053000	usd
CY2021	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	116000	shares
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9903000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-48000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	24000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	296000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	248000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	24000	usd
CY2023Q4	med	Cash And Cash Equivalents Excluding Money Market Accounts Amortized Cost CashAndCashEquivalentsExcludingMoneyMarketAccountsAmortizedCost	88778000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	88778000	usd
CY2023Q4	med	Investment Securities Accrued Interest InvestmentSecuritiesAccruedInterest	310000	usd
CY2023Q4	med	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	150041000	usd
CY2022Q4	med	Cash And Cash Equivalents Excluding Money Market Accounts Amortized Cost CashAndCashEquivalentsExcludingMoneyMarketAccountsAmortizedCost	87691000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	87691000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	87691000	usd
CY2022Q4	med	Investment Securities Unrealized Gains InvestmentSecuritiesUnrealizedGains	0	usd
CY2022Q4	med	Investment Securities Accrued Interest InvestmentSecuritiesAccruedInterest	0	usd
CY2022Q4	med	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	87691000	usd
CY2023	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	150000	usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0	usd
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0	usd
CY2023	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	150000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	usd
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	25170000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	35857000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	49433000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3001000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5558000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6380000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	28171000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	41415000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	55813000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1523000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-738000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3424000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-312000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-186000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-291000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1211000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-924000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3715000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29382000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40491000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52098000	usd
CY2023	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	29500000	usd
CY2022	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	40500000	usd
CY2021	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	52200000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29382000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40491000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52098000	usd
CY2023	med	Unrealized Gain Loss On Investment Securities And Foreign Currency Income Tax Effects Allocated To Equity UnrealizedGainLossOnInvestmentSecuritiesAndForeignCurrencyIncomeTaxEffectsAllocatedToEquity	112000	usd
CY2022	med	Unrealized Gain Loss On Investment Securities And Foreign Currency Income Tax Effects Allocated To Equity UnrealizedGainLossOnInvestmentSecuritiesAndForeignCurrencyIncomeTaxEffectsAllocatedToEquity	-27000	usd
CY2021	med	Unrealized Gain Loss On Investment Securities And Foreign Currency Income Tax Effects Allocated To Equity UnrealizedGainLossOnInvestmentSecuritiesAndForeignCurrencyIncomeTaxEffectsAllocatedToEquity	66000	usd
CY2023	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	29494000	usd
CY2022	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	40464000	usd
CY2021	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	52164000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	27048000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	38621000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	45405000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	2124000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.017
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	4635000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.025
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	4980000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.023
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	143000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.001
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-26000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1835000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.008
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1258000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.010
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	819000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.004
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	503000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.002
CY2023	med	Effective Income Tax Rate Reconciliation Nondeductible Expense Other Amount Executive Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherAmountExecutiveCompensation	1895000	usd
CY2023	med	Effective Income Tax Rate Reconciliation Nondeductible Expense Other Executive Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherExecutiveCompensationPercent	0.015
CY2022	med	Effective Income Tax Rate Reconciliation Nondeductible Expense Other Amount Executive Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherAmountExecutiveCompensation	1470000	usd
CY2022	med	Effective Income Tax Rate Reconciliation Nondeductible Expense Other Executive Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherExecutiveCompensationPercent	0.008
CY2021	med	Effective Income Tax Rate Reconciliation Nondeductible Expense Other Amount Executive Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherAmountExecutiveCompensation	2652000	usd
CY2021	med	Effective Income Tax Rate Reconciliation Nondeductible Expense Other Executive Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOtherExecutiveCompensationPercent	0.012
CY2023	med	Effective Income Tax Rate Reconciliation Charitable Donations EffectiveIncomeTaxRateReconciliationCharitableDonations	1094000	usd
CY2023	med	Effective Income Tax Rate Reconciliation Charitable Donations Percent EffectiveIncomeTaxRateReconciliationCharitableDonationsPercent	0.008
CY2022	med	Effective Income Tax Rate Reconciliation Charitable Donations EffectiveIncomeTaxRateReconciliationCharitableDonations	4316000	usd
CY2022	med	Effective Income Tax Rate Reconciliation Charitable Donations Percent EffectiveIncomeTaxRateReconciliationCharitableDonationsPercent	0.023
CY2021	med	Effective Income Tax Rate Reconciliation Charitable Donations EffectiveIncomeTaxRateReconciliationCharitableDonations	0	usd
CY2021	med	Effective Income Tax Rate Reconciliation Charitable Donations Percent EffectiveIncomeTaxRateReconciliationCharitableDonationsPercent	-0.000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-613000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.005
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	396000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.002
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	468000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.002
CY2023	med	Effective Income Tax Rate Reconciliation Intercompany Loan Restructuring EffectiveIncomeTaxRateReconciliationIntercompanyLoanRestructuring	1167000	usd
CY2023	med	Effective Income Tax Rate Reconciliation Intercompany Loan Restructuring Percent EffectiveIncomeTaxRateReconciliationIntercompanyLoanRestructuringPercent	0.009
CY2022	med	Effective Income Tax Rate Reconciliation Intercompany Loan Restructuring EffectiveIncomeTaxRateReconciliationIntercompanyLoanRestructuring	0	usd
CY2022	med	Effective Income Tax Rate Reconciliation Intercompany Loan Restructuring Percent EffectiveIncomeTaxRateReconciliationIntercompanyLoanRestructuringPercent	0
CY2021	med	Effective Income Tax Rate Reconciliation Intercompany Loan Restructuring EffectiveIncomeTaxRateReconciliationIntercompanyLoanRestructuring	0	usd
CY2021	med	Effective Income Tax Rate Reconciliation Intercompany Loan Restructuring Percent EffectiveIncomeTaxRateReconciliationIntercompanyLoanRestructuringPercent	0
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	106000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.001
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	427000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.002
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	808000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.004
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29382000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.228
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40491000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.220
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52098000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.241
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	721000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1069000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2881000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3713000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1784000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2374000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2986000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	5153000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	587000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	1781000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	5542000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	5773000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5841000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2502000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	114000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	1862000	usd
CY2023Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	1520000	usd
CY2022Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	164000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	190000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1680000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2523000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	20460000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21894000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3938000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4089000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	2084000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	1289000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	10321000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	11165000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	23000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	16343000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	16566000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	4117000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	5328000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	28700000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7500000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	6200000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6000000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	4800000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6011000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2714000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1744000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	860000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	38000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2487000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	291000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	50000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7502000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6011000	usd
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	1300000	usd
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	900000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	300000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	200000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	5100000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	6700000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	5600000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	6333000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	7199000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1785000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	101000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P48M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.023
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6312000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6462000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4783000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2553000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2618000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	240000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	22968000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	956000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	22012000	usd

Files In Submission

Name	View Source	Status
0001628280-24-005620-index-headers.html	Edgar Link	pending
0001628280-24-005620-index.html	Edgar Link	pending
0001628280-24-005620.txt	Edgar Link	pending
0001628280-24-005620-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
med-20231231.htm	Edgar Link	pending
med-20231231.xsd	Edgar Link	pending
med-20231231x10kxex211.htm	Edgar Link	pending
med-20231231x10kxex231.htm	Edgar Link	pending
med-20231231x10kxex311.htm	Edgar Link	pending
med-20231231x10kxex312.htm	Edgar Link	pending
med-20231231x10kxex32.htm	Edgar Link	pending
med-20231231x10kxex97.htm	Edgar Link	pending
med-20231231_g1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
med-20231231_cal.xml	Edgar Link	unprocessable
med-20231231_def.xml	Edgar Link	unprocessable
med-20231231_lab.xml	Edgar Link	unprocessable
med-20231231_htm.xml	Edgar Link	completed
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
med-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MED
MEDIFAST INC Stock $med

2024 Q1 Form 10-K Financial Statement

#000162828024005620 Filed on February 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MED MEDIFAST INC Stock $med

2024 Q1 Form 10-K Financial Statement

#000162828024005620 Filed on February 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MED
MEDIFAST INC Stock $med